{"version":"1.0","provider_name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","provider_url":"https:\/\/www.izb-online.de\/en\/","title":"\u201cWomen should be more confident!\u201d","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Qemx3qekkp\"><a href=\"https:\/\/www.izb-online.de\/en\/frauen-sollen-sich-mehr-zutrauen\/\">\u201cWomen should be more confident!\u201d<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.izb-online.de\/en\/frauen-sollen-sich-mehr-zutrauen\/embed\/#?secret=Qemx3qekkp\" width=\"600\" height=\"338\" title=\"&#8220;\u201cWomen should be more confident!\u201d&#8221; &#8212; Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\" data-secret=\"Qemx3qekkp\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.izb-online.de\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Bild-1_Frauen-in-der-Biotechnologie_Stories_20172_Kohlhof_beitragsbild_stories.jpg","thumbnail_width":900,"thumbnail_height":445,"description":"\u00adImmunic AG is a young biotech company and a management buy-out from 4SC AG. With an investment volume of USD 22 million in the series A the company develops small molecule drugs for chronic inflammatory and autoimmune diseases. Immunic\u2019s main focus is on inflammatory bowel diseases such as ulcerative colitis and Crohn\u2019s disease, and also psoriasis. As CSO of Immunic, Dr. Kohlhof is responsible for the company\u2019s research activities and strategy. She is convinced that Immunic is going to develop outstanding therapeutic products that will sustainably improve the therapeutic options for chronic inflammatory diseases. A Phase 2b clinical study will start at the end of 2017. Dr. Kohlhof expects an exit based on clinical proof-of-concept data in three to four years, e.g. sale of the company. Susanne Simon and Rainer Rutz interviewed her for \u201cIZB in Dialogue\u201d."}